Article
Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants.
Antiviral therapy - 1 Jan 2014
Solmone Mariacarmela, Giombini Emanuela, Vincenti Donatella, Rozera Gabriella, Testa Angela, Moscetti Alessandra, Catalano Manuela, Abbate Isabella, Capobianchi Maria R, Menzo Stefano
Abstract excerpt
BACKGROUND: Entecavir is the drug of choice as first-line treatment for treatment-naive HBV patients. As a result of the high genetic barrier to resistance, treatment failure remains rare, but occurs within 3 years of initiation, suggesting that viral genetic characteristics may provide a fast lane to resistance. One of the main concerns is the long time to viral suppression observed in some (even...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.